Pipeline Therapeutics

📍 San Diego, United States🗓 Founded 2017👥 34 employees💰 Last funded May 2023
Pharmaceutical Manufacturing🌐 pipelinetherapeutics.com
Website LinkedIn
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s second program, PIPE-791, an LPA1 receptor antagonist, has received FDA clearance of its IND and is advancing into Phase 1 testing.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Pipeline Therapeutics?
Pipeline Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Pipeline Therapeutics last raise funding?
The most recent investment in Pipeline Therapeutics recorded on gritt.io was in May 2023.
When was Pipeline Therapeutics founded?
Pipeline Therapeutics was founded in 2017.
What industry is Pipeline Therapeutics in?
Pipeline Therapeutics operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Pipeline Therapeutics based?
Pipeline Therapeutics is headquartered in San Diego, United States.